Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mersana Therapeutics Inc (MRSN)

Mersana Therapeutics Inc (MRSN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 139,216
  • Shares Outstanding, K 4,999
  • Annual Sales, $ 40,500 K
  • Annual Income, $ -69,190 K
  • EBIT $ -72 M
  • EBITDA $ -74 M
  • 60-Month Beta 0.45
  • Price/Sales 3.40
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 0.00% (unch)
  • Historical Volatility 327.90%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 986.44% on 11/28/25
  • IV Low 0.00% on 12/04/25
  • Expected Move (DTE 43) 0.09 (0.31%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 303
  • Volume Avg (30-Day) 245
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 4,775
  • Open Int (30-Day) 10,835
  • Expected Range 27.59 to 27.76

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -2.89
  • Number of Estimates 4
  • High Estimate -1.56
  • Low Estimate -3.72
  • Prior Year -2.75
  • Growth Rate Est. (year over year) -5.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.54 +264.32%
on 11/07/25
28.36 -3.14%
on 12/04/25
+19.31 (+236.64%)
since 11/04/25
3-Month
6.63 +314.21%
on 09/08/25
28.36 -3.14%
on 12/04/25
+20.35 (+285.81%)
since 09/04/25
52-Week
5.21 +427.26%
on 08/13/25
70.73 -61.16%
on 12/09/24
-29.28 (-51.59%)
since 12/04/24

Most Recent Stories

More News
Halper Sadeh LLC Encourages SEMR, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

SEMR : 11.84 (unch)
MRSN : 27.47 (-1.36%)
EXAS : 101.13 (-0.12%)
HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm Continues to Investigate the Merger - EXAS, SEE, CDTX, and MRSN

NEW YORK , Nov. 27, 2025 / PRNewswire/ --

SEE : 42.28 (-0.45%)
MRSN : 27.47 (-1.36%)
EXAS : 101.13 (-0.12%)
CDTX : 220.50 (-0.22%)
Halper Sadeh LLC Encourages RPTX, SEE, CDTX, MRSN Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

SEE : 42.28 (-0.45%)
MRSN : 27.47 (-1.36%)
RPTX : 2.23 (+2.76%)
CDTX : 220.50 (-0.22%)
Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc. - MRSN

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Mersana Therapeutics...

MRSN : 27.47 (-1.36%)
Halper Sadeh LLC Encourages CDTX, MRSN, HOLX Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

HOLX : 74.86 (-0.20%)
MRSN : 27.47 (-1.36%)
CDTX : 220.50 (-0.22%)
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2025 Financial Results

Day One Biopharmaceuticals, Inc. to Acquire Mersana Therapeutics, Inc. Agreement provides for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments...

MRSN : 27.47 (-1.36%)
Shareholder Alert: The Ademi Firm investigates whether Mersana Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE , Nov. 13, 2025 /PRNewswire/ -- The Ademi Firm is investigating Mersana (NASDAQ: MRSN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction...

MRSN : 27.47 (-1.36%)
MRSN Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Mersana Therapeutics, Inc. is Fair to Shareholders

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

MRSN : 27.47 (-1.36%)
Day One Biopharmaceuticals to Acquire Mersana Therapeutics

Agreement with Day One Biopharmaceuticals provides for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments of up to an aggregate of $30.25 per share,...

MRSN : 27.47 (-1.36%)
Mersana Therapeutics to Host Third Quarter 2025 Conference Call on November 14, 2025

CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs)...

MRSN : 27.47 (-1.36%)

Business Summary

Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company's product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States.

See More

Key Turning Points

3rd Resistance Point 29.17
2nd Resistance Point 28.76
1st Resistance Point 28.12
Last Price 27.47
1st Support Level 27.07
2nd Support Level 26.66
3rd Support Level 26.02

See More

52-Week High 70.73
Fibonacci 61.8% 45.70
Fibonacci 50% 37.97
Fibonacci 38.2% 30.24
Last Price 27.47
52-Week Low 5.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar